AzN’s tozorakimab shows broad COPD efficacy; FDA priority review
Tozorakimab demonstrated significant reductions in COPD exacerbations across patient subgroups. The program has FDA priority review and is projected to peak sales exceeding $5 billion.
Tozorakimab showed significant reductions in COPD exacerbations across all patient subgroups, underscoring its potential as a first-in-class biologic for a broad patient population. The drug has FDA priority review and projected peak sales exceeding $5 billion, and is being positioned to address a large unmet need.